Predicate |
Object |
assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_2bf500638408a6d01cae7fa3c80238aa |
classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2319-30 |
classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P37-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-70578 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-17 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-1793 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-177 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P29-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0053 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-395 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0019 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P37-00 |
classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P29-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-395 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P25-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P37-00 |
filingDate |
2019-05-15-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_877b0c2849c7689217b95c4b09320fc3 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_3b69b8e1648d59bb7f5dea99167299d0 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_4982efd97167fc4c0782f1e8534e1c51 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_576a398dfa7460b7f6c638f76f5f5b71 |
publicationDate |
2019-11-28-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
publicationNumber |
WO-2019223581-A1 |
titleOfInvention |
Application of taci-fc fusion protein in preparation of drugs for treating neuromyelitis optica spectrum disorders and multiple sclerosis |
abstract |
The present invention relates to the field of B-lymphocyte stimulator receptor-antibody fusion proteins for treating autoimmune diseases, and in particular to a TACI-Fc fusion protein in preparation of drugs for treating neuromyelitis optica spectrum disorders (NMOSD) and multiple sclerosis (MS). |
isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/RU-2779387-C1 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-3868403-A4 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11274140-B2 |
priorityDate |
2018-05-25-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
type |
http://data.epo.org/linked-data/def/patent/Publication |